WAVE Life Sciences (NASDAQ:WVE) Stock Rating Upgraded by Wall Street Zen

WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently commented on the company. Mizuho dropped their target price on WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. LADENBURG THALM/SH SH initiated coverage on shares of WAVE Life Sciences in a research note on Thursday, October 1st. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright began coverage on WAVE Life Sciences in a research report on Wednesday, October 28th. They set a “strong-buy” rating for the company. Wedbush set a $13.00 price objective on WAVE Life Sciences in a research note on Friday, October 2nd. Finally, JPMorgan Chase & Co. assumed coverage on shares of WAVE Life Sciences in a research note on Wednesday, September 23rd. They issued a “neutral” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.89.

WAVE Life Sciences Price Performance

NASDAQ WVE opened at $3.59 on Friday. The company has a fifty day moving average of $4.07 and a 200 day moving average of $7.49. WAVE Life Sciences has a 1 year low of $3.04 and a 1 year high of $21.73. The company has a market capitalization of $708.05 million, a PE ratio of -3.36 and a beta of -1.43.

WAVE Life Sciences (NASDAQ:WVE) last posted its earnings results on Tuesday, October 27th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $13.16 million for the quarter, compared to analysts’ expectations of $4.51 million. WAVE Life Sciences had a negative return on equity of 44.66% and a negative net margin of 296.86%. Research analysts expect that WAVE Life Sciences will post -1.09 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Adrian Rawcliffe sold 12,700 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total transaction of $67,183.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Heidi L. Wagner sold 7,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total value of $42,070.00. Following the sale, the director directly owned 44,930 shares of the company’s stock, valued at $270,029.30. This represents a 13.48% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 23,564 shares of company stock valued at $132,476. 24.34% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On WAVE Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AlphaCentric Advisors LLC raised its holdings in shares of WAVE Life Sciences by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 29,175 shares of the company’s stock worth $212,000 after acquiring an additional 1,585 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of WAVE Life Sciences by 15.7% in the first quarter. First Trust Advisors LP now owns 13,518 shares of the company’s stock valued at $98,000 after purchasing an additional 1,830 shares in the last quarter. Arizona State Retirement System increased its position in WAVE Life Sciences by 17.1% in the second quarter. Arizona State Retirement System now owns 35,826 shares of the company’s stock worth $208,000 after purchasing an additional 5,228 shares during the last quarter. Quantinno Capital Management LP increased its position in WAVE Life Sciences by 23.0% in the first quarter. Quantinno Capital Management LP now owns 47,885 shares of the company’s stock worth $347,000 after purchasing an additional 8,960 shares during the last quarter. Finally, AlphaGrep UK Ltd bought a new stake in WAVE Life Sciences in the second quarter worth $78,000. 89.73% of the stock is owned by institutional investors.

WAVE Life Sciences News Summary

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported third-quarter revenue of $13.16 million, well above the $4.51 million analyst consensus, while its $0.30 per-share loss was narrower than the expected $0.33 loss. The results helped ease concerns about the company’s financial performance and contributed to a recent share-price rally. Wave Life Sciences stock rallies as Q3 results ease loss fears
• Positive Sentiment: HC Wainwright initiated coverage with a “Strong-Buy” rating, offering a favorable view of WAVE’s long-term prospects. The firm forecasts a $1.09-per-share loss for fiscal 2026 and fiscal 2027, improving to losses of $0.79 in fiscal 2028, $0.68 in fiscal 2029 and $0.47 in fiscal 2030. HC Wainwright stock recommendations
• Neutral Sentiment: HC Wainwright’s quarterly forecasts call for continued losses, ranging from $0.26 to $0.31 per share through the near-term reporting periods. The estimates imply that investors will likely focus on clinical progress, revenue growth and the company’s ability to reduce cash burn rather than near-term profitability.
• Negative Sentiment: Despite beating estimates, WAVE remains deeply unprofitable, with a negative net margin and analyst expectations for another full-year loss. Its shares also remain well below the 52-week high, reflecting continuing execution and biotechnology-sector risks.

About WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.